<DOC>
	<DOCNO>NCT01323257</DOCNO>
	<brief_summary>The purpose study investigate effect steady-state concentration erythromycin DRV/r steady-state pharmacokinetics TMC435 , effect steady-state concentration TMC435 ( 150 mg ) steady-state pharmacokinetics erythromycin effect steady-state concentration TMC435 ( 50 mg ) steady-state pharmacokinetics DRV/r . We also study short-term safety tolerability TMC435 give alone give togehter erythromycin ( Panel 1 ) DRV/r ( Panel 2 ) . Steady state term mean drug give long enough plasma concentration remain subsequent dose . TMC435 investigate treatment chronic hepatitis C virus ( HCV ) infection . Pharmacokinetics ( PK ) mean drug absorb bloodstream , distribute body , eliminate body .</brief_summary>
	<brief_title>TMC435-TiDP16-C115 - A Study Healthy Volunteers Investigating Pharmacokinetic Interaction Between TMC435 Erythromycin Between TMC435 Darunavir/Ritonavir ( DRV/r )</brief_title>
	<detailed_description>TMC435 investigate treatment chronic hepatitis C virus ( HCV ) infection , combination Peg-IFN ( pegylated interferon ) RBV ( ribavirin ) . Erythromycin antibiotic Darunavir/ritonavir ( DRV/r ) currently indicate treatment HIV infection . TMC435 metabolize degradation enzyme CYP3A . Erythromycin DRV/r respectively moderate strong inhibitor degradation enzyme CYP3A . The result study provide dose recommendation TMC435 erythromycin DRV/r , coadministered . This Phase I , open-label ( participant investigator know name medication give certain moment ) , randomize ( sequence treatment study medication assign chance ) , crossover trial 48 healthy volunteer investigate pharmacokinetic interaction TMC435 , steady state , DRV/r erythromycin , steady-state . The volunteer allocate one two panel . In Panel 1 , volunteer receive three treatment ( Trts A , B C ) randomize order . Volunteers receive TMC435 150 mg daily 7 day ( Trt A ) erythromycin 500 mg three time daily 6 day + morning dose day 7 ( Trt B ) TMC435 150 mg daily 7 day + erythromycin 500 mg three tmes daily 7 day ( Trt C ) . In Panel 2 , volunteer receive three treatment ( Trts D , E F ) randomize order . Volunteers receive TMC435 150 mg daily 7 day ( Trt D ) , DRV/r 800/100 mg daily 7 day ( Trt E ) TMC435 50 mg daily 7 day + DRV/r 800/100 mg daly 7 day ( Trt F ) . In panel , washout period ( period study drug take , order medication eliminate body start new treatment ) least 10 ( Panel 1 ) 7 ( Panel 2 ) day last intake study medication one session first intake study medication subsequent session . Pharmacokinetic profile four compound ( TMC435 , DRV , ritonavir erythromycin ) determine blood sample take regular interval study . Safety tolerability assess study period follow . Blood urine sample , electrocardiogram ( ECG ) vital sign ( blood pressure heart rate ) take screening , Day 1 , Day 7 Day 8 follow visit 1 week last dose study medication last session . A physical examination perform screening , Day -1 ( = day first medication intake session panel ) Day 1 , Day 8 follow-up visit . Volnteers admit unit Day-1 , discharge Day2 , re-admitted Day6 discharge Day8 . Each volunteer follow 3 treatment ( Trt ) period , minimum 10 day ( Panel 1 ) 7 day ( Panel 2 ) apart . All treatment period take 7 day drug oral intake . Panel 1 : Trt A = 150 mg TMC435 daily ; Trt B = 500 mg erythromycin three time daily ; Trt C : combining Trt A + B . Panel 2 : Trt D = Trt A ; Trt E = 800/100 mg DRV/r daily ; Trt D = 50 mg TMC435 daily + Trt E .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Erythromycin stearate</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<mesh_term>Erythromycin Estolate</mesh_term>
	<mesh_term>Erythromycin Ethylsuccinate</mesh_term>
	<criteria>Nonsmoker least 3 month Body Mass Index 18.0 30.0 kg/m2 Healthy base medical evaluation include medical history , physical examination , blood test , vital sign , electrocardiogram Infection hepatitis A , B C virus Infection human immunodeficiency virus ( HIV ) History current medical condition could impact safety participant study Having previously dose TMC435 multipledose trial TMC435 Having previously dose TMC435 3 singledose trial TMC435</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>TMC435-TiDP16-C115</keyword>
	<keyword>TMC435-C115</keyword>
	<keyword>TMC435</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hep C</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>